The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
Abstract
Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], β2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease. (Blood. 2004;104:1624-1630)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Report of the Committee on Hodgkin's Disease Staging Classification.
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971) · PubMed · Cited by 4,166
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
UPDATED KIEL CLASSIFICATION FOR LYMPHOMAS
Stansfeld, A. G., Diebold, J., Kapanci, Y., Kelényi, G., Lennert, K., Mioduszewska, O., Noel, H., Rilke, F., Sundstrom, C., Van Unnik, J. A. M., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90367-4 · Cited by 1,149
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Self-citationKantarjian, H. M., Smith, T. L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., & Service*, A. T. L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-4-199502150-00003 · Cited by 417
Self-citationClinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia
Faderl, S., Kantarjian, H. M., Talpaz, M., & Estrov, Z. (1998) · Blood · doi:10.1182/blood.v91.11.3995 · Cited by 335
Self-citation
Cited by
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Kantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso‐Ramos, C. E., Pierce, S., Shan, J., Koller, C., et al. (2004) · Cancer · doi:10.1002/cncr.20668 · Cited by 638
Self-citationThomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Self-citationChalandon, Y., Thomas, X., Hayette, S., Cayuela, J.-M., Abbal, C., Huguet, F., Raffoux, E., Leguay, T., Rousselot, P., Lepretre, S., et al. (2015) · Blood · doi:10.1182/blood-2015-02-627935 · Cited by 379
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Egler, R. A., Ahuja, S. P., & Matloub, Y. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.184769 · Cited by 334
Metadata
- Authors
- Thomas, D. A., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Verstovsek, S., Ferrajoli, A., Koller, C., Beran, M., Pierce, S., Ha, C. S., Cabanillas, F., Keating, M. J., & Kantarjian, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-09-15
- Volume
- 104
- Issue
- 6
- Pages
- 1624-1630
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2104165703
- Cited by
- 255
- References
- 12
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. https://app.cochat.ai/papers/10.1182/blood-2003-12-4428
- The paper
- Thomas, D. A., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Verstovsek, S., Ferrajoli, A., Koller, C., Beran, M., Pierce, S., Ha, C. S., Cabanillas, F., Keating, M. J., & Kantarjian, H. (2004). Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. https://doi.org/10.1182/blood-2003-12-4428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.